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Purpose: The literature and clinical data support the
use of intravenous (IV) infusions of ibuprofen to control
pain and reduce the opioid requirements associated with
surgical pain. According to current guidelines, IV ibupro-
fen can be administered via a slow IV infusion performed
during a 30-minute period. Although recent studies
indicate that more rapid infusions may yield additional
beneﬁts for patients, the safety of such an approach needs
further evaluation. The main purpose of this study was to
determine the safety of single and multiple doses of IV
ibuprofen (800 mg) administered over 5 to 10 minutes at
the induction of anesthesia and after the surgical proce-
dure for the treatment of postoperative pain.
Methods: This was a Phase IV, multicenter, open-
label, clinical surveillance study. It was conducted at 21
hospitals in the United States, and 300 adult hospi-
talized patients undergoing surgery were enrolled. The
exclusion criteria for the study were: inadequate IV
access; hypersensitivity to any component of IV ibu-
profen, aspirin, or related products; and any active,
clinically signiﬁcant bleeding. Also excluded were
patients who had taken NSAIDs o6 hours before
administration of IV ibuprofen; pregnant or breastfeed-
ing female patients; and patients in the perioperative
period of coronary artery bypass graft surgery. Patients368received 800 mg of IV ibuprofen administered over 5 to
10 minutes preoperatively. Vital signs, adverse events,
and pain scores were assessed.
Findings: Approximately 22% (65 of 300) of patients
reported adverse events (serious and nonserious). The
most common adverse event was infusion site pain (34
of 300 [11%]). No deaths were reported. Nine subjects
reported serious adverse events, 8 of which occurred
during the ﬁrst 6 hours. All serious events reported were
judged unrelated to ibuprofen. Of the 300 total patients,
2 (0.67%) discontinued the study drug due to an adverse
event (1 patient discontinued the study because of
infusion site pain, and 1 patient withdrew due to a
hypersensitivity reaction after drug administration).
Implications: Our study found that IV ibuprofen
infused over 5 to 10 minutes at induction of anesthesia
is a safe administration option for surgical patients.
ClinicalTrials.gov identiﬁer: NCT01334957. (Clin Ther.
2015;37:368–375) & 2015 The Authors. Published by
Elsevier HS Journals, Inc.Volume 37 Number 2
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Although the importance of controlling postoperative
pain is widely accepted, achieving this goal remains a
challenge.1 The 2012 Updated Report by the American
Society of Anesthesiologists Task Force on Acute Pain
Management recommends a multimodal appro-
ach to pain management.2 The task force agrees that,
unless contraindicated, patients should receive an around-
the-clock regimen of NSAIDs, cyclooxygenase-2
selective inhibitors, and/or acetaminophen. Following
this guidance and using a multimodal approach,
numerous randomized, double-blind, placebo-control-
led trials were conducted in surgical patients under-
going orthopedic procedures evaluating both pain
reduction and the opioid-sparing effects of intrave-
nous (IV) ibuprofen. These studies demonstrated a
signiﬁcant reduction in pain and a morphine-sparing
effect when IV ibuprofen therapy (each dose infused
over 30 minutes) was initiated, either at induction of
anesthesia or perioperatively.3–5
Although the 30-minute infusion of IV ibuprofen
has been shown to be safe and efﬁcacious, further
shortening of the infusion time may provide additional
beneﬁts. A 5- to 10-minute infusion of IV ibuprofen
would signiﬁcantly shorten the Tmax and time of onset
of the therapeutic action compared with the 30- to 60-
minute infusion protocol or peroral administration. It
would then eliminate any variability in ibuprofen’s
pharmacodynamics associated with the variable ab-
sorption rate of the orally administered formulation of
the drug.6 These factors are particularly critical in the
perioperative period, during which time and pain are
closely related. Emergency medicine is another
specialty in which rapid infusion of IV ibuprofen
may prove beneﬁcial.
A recent study in healthy subjects found that a
shortened infusion time of 5 to 7 minutes for IV
ibuprofen is well tolerated and results in a higher Cmax
and shorter Tmax compared with a 30-minute infusion
or oral administration.7 Subsequently, a Phase IV,
multicenter, open-label, surveillance safety study
found that a shortened infusion time of IV ibuprofen
can be safely administered in hospitalized patientsFebruary 2015experiencing fever or mild to moderate or moderate to
severe pain.8
The present trial was designed to further evaluate
the safety of a shortened infusion time of IV ibuprofen
in surgical patients. We hypothesized that a shortened
infusion time in surgical patients would present no
additional risks compared with a 30-minute infusion
period.
PATIENTS AND METHODS
This Phase IV, multicenter, open-label, clinical sur-
veillance study was designed to assess the safety of IV
ibuprofen administered over 5 to 10 minutes to
hospitalized adult patients undergoing surgical proce-
dures. The study was approved by site-speciﬁc institu-
tional review boards. Adults (ie, aged Z18 years)
scheduled for surgery and with an anticipated need for
postoperative analgesia were eligible for study inclu-
sion. Exclusion criteria included: inadequate IV access
(ie, difﬁculties in securing reliable IV access by using a
Z20-gauge diameter catheter); history of allergy or
hypersensitivity to any component of IV ibuprofen or
aspirin (or related products); or any active, clinically
signiﬁcant bleeding. Patients were excluded from
enrollment if they had taken NSAIDso6 hours before
IV ibuprofen administration; also excluded were
pregnant or breastfeeding female patients or patients
in the perioperative period of coronary artery bypass
graft surgery.
Eligible patients received up to 4 doses of 800 mg
of IV ibuprofen, administered at 6-hour intervals,
depending on patient requirements. The ﬁrst dose of
IV ibuprofen was administered before the surgical
procedure, approximately at the time of induction of
anesthesia. The drug was diluted in saline and ad-
ministered at a concentration of r4 mg/mL over 5 to
10 minutes. The use of the 800-mg preoperative dose
of IV ibuprofen was based on the product package
insert and previous surgical studies.3–5,9 All NSAIDs
(excluding ibuprofen) were restricted during the treat-
ment and posttreatment periods. There was no formal
anesthesia protocol.
Assessments
To evaluate the safety of a single dose of IV
ibuprofen administered over 5 to 10 minutes for the
treatment of postoperative pain, vital signs were
recorded at baseline and 4 hours after the initial IV
ibuprofen infusion. The incidence of adverse events369
Clinical Therapeuticsoccurring over the 6 hours after administration of IV
ibuprofen was recorded. In addition, each site inves-
tigator assessed the association between any adverse
event and IV ibuprofen.
To evaluate the safety of multiple doses of IV
ibuprofen administered over 5 to 10 minutes for the
treatment of postoperative pain, the incidence of
adverse events occurring within the 6 hours after
administration of the last dose of IV ibuprofen was
collected.
Pain intensity was measured over the subsequent 6
hours after the initial drug infusion. No comparative
analysis of IV ibuprofen versus the standardized pain
management was conducted. In this multicenter, open-
label, clinical surveillance study, visual analog scale
(VAS) scores were assessed to verify adequate pain
relief comparable to published reports in the litera-
ture. Pain intensity was quantiﬁed based on patients’
self-assessment, performed by using a 0- to 100-mm
VAS (0 mm indicating no pain and 100 mm indicating
intense pain).
Statistical Analysis
Formal sample size calculations were not per-
formed, nor were formal statistical tests applied to
assess the differences before and after the drug
infusion. The intent of the present study was to enroll
patients to provide descriptive safety and efﬁcacy data
on perioperative rapid infusions of IV ibuprofen.
Considering this design and the realistic assessment
of patient numbers that could be recruited in such a
multicenter study, the overall number of 300 patients
was considered adequate for safety assessment of a
shortened IV ibuprofen infusion as well as monitoring
of the dynamics of pain severity during the study
period.
Continuous data were summarized in tables listing
means and SDs. When appropriate, the data are
presented as absolute numbers and percentages rela-
tive to the overall number of patients. Categorical
data are summarized by using absolute numbers and
percentages. The descriptive statistical analysis was
conducted by using SAS version 9.1.3 (SAS Institute,
Inc, Cary, North Carolina).
RESULTS
Twenty-one clinical centers in the United States
enrolled patients (Table I). A total of 300 surgical
patients were enrolled in the study; their mean age was37051 (13.4) years. Demographic characteristics are
presented in Table II. Of the 300 enrolled patients,
252 (84%) received a single dose of IV ibuprofen
administered before the surgical procedure, and 48
(16%) patients received Z2 doses (preprocedure and
postprocedure) (Table III). From the 300 patients
enrolled, the most common surgical procedures
included hernia repair, n ¼ 41 (14%); hysterectomy,
n ¼ 40 (13%); and cholecystectomy, n ¼ 29 (10%)
(Table IV).
No signiﬁcant differences in vital signs were ob-
served between the preanesthesia period and 4 hours’
postsurgery (Table V). Adverse events were reported
for 65 (22%) of the 300 patients. Of the 65 patients
experiencing adverse events, most events were mild to
moderate in intensity (57 of 65 [88%]). Of the 252
patients who received a single dose of IV ibuprofen
administered before the surgical procedures, 49 (19%)
experienced an adverse event within 6 hours of
ibuprofen administration. Of the 48 patients who
received IV ibuprofen both presurgery and
postsurgery, 16 (33%) experienced an adverse event
within 6 hours after the last dose of IV ibuprofen
(Table VI).
The most common adverse event experienced by
patients was pain or discomfort at the infusion site (42
of 300 [14%]). Other adverse events reported by
43% of patients included nausea, ﬂatulence, anemia,
and bradycardia (Table VII). Excluding infusion site
reactions, most adverse events were considered
unrelated to IV ibuprofen in the opinion of the
investigator. Bradycardia events were categorized as
not related to IV ibuprofen in the opinion of the
investigator. Nine serious adverse events were
reported. Serious events and the investigator’s
assessment of relationship to IV ibuprofen are
presented in Table VIII.
Two (0.67%) of the 300 patients discontinued the
study drug due to an adverse event. One patient
discontinued study drug due to infusion site pain,
and 1 patient withdrew from the study due to a
systemic hypersensitivity reaction.
Pain scores were collected during the postoperative
period. The postoperative analgesia regimen was not
controlled, allowing study sites to follow their standard
postoperative pain management protocol. In the 6 hours
after drug administration, mean VAS scores ranged
from 26.3 to 33.4 mm. The mean (SD) values of the
VAS for each time point are depicted in the Figure.Volume 37 Number 2
Table I. List of investigators and institutions participating in the multicenter study.
Investigator Institution Location
Sanjib Adhikary, MD Penn State University Medical Center Hershey, PA
Sergio D. Bergese, MD The Ohio State University Medical Center Columbus, OH
Richard L. Boortz-Marx, MD University of North Carolina Chapel Hill, NC
David Broussard, MD Ochsner Health New Orleans, LA
Asokumar Buvanendran, MD Rush University Medical Center Chicago, IL
Keith A. Candiotti, MD University of Miami Health System Miami, FL
James C. Crews, MD Wake Forest University Winston-Salem, NC
Martin DeRuyter, MD University of Kansas Medical Center Kansas City, KS
Timothy J. Furnish, MD University of California at San Diego San Diego, CA
Tong J. Gan, MD Duke University Medical Center Durham, NC
Peter Kroll, MD Comprehensive Pain Specialists Hendersonville, TN
Eric J. Grigsby, MD Napa Pain Institute Napa, CA
John Lovecchio, MD North Shore Hospital Lake Success, NY
Dawood Nasir, MD Parkland Memorial Hospital Dallas, TX
Beverly K. Philip, MD Brigham & Women's Hospital Boston, MA
Juan Restrepo, MD Sheridan Clinical Research Sunrise, FL
Howard S. Smith, MD Albany Medical Center Albany, NY
Stephen R. Southworth, MD North Mississippi Medical Center Tupelo, MS
Alparslan Turan, MD Cleveland Clinic Cleveland, OH
Rebecca Twersky, MD State University of New York Downstate Brooklyn, NY
Eugene Viscusi, MD Thomas Jefferson University Hospital Philadelphia, PA
Table II. Demographic and baseline charac-
teristics of patients (N ¼ 300).
Characteristic Intravenous Ibuprofen
Age, y* 51 (13.4)
Weight, kg* 84.6 (19)
Sex, no. (%)
Male 111 (37)
Female 189 (63)
Race, no. (%)
White 229 (76)
Black 60 (20)
Asian 5 (2)
Other 6 (2)
Ethnicity, no. (%)
Hispanic/Latino 29 (10)
Not Hispanic/Latino 271 (90)
*Mean (SD).
T.J. Gan et al.
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Treatment of postoperative pain continues to be a
challenge. Ibuprofen effectively reduces pain and
inﬂammation by reducing prostaglandin synthesis.10
An IV formulation of ibuprofen has the potential to
quickly reduce postoperative pain by arresting the
inﬂammatory cascade caused by surgical procedures.
In a previous multicenter, randomized, placebo-con-
trolled trial conducted in orthopedic surgical patients,
pain reduction and the opioid-sparing effect of IV
ibuprofen were evaluated as part of multimodal post-
operative pain management in which the ﬁrst dose of
800 mg IV ibuprofen was administered before the
surgical procedure and therapy was continued for at
least 24 hours (doses administered every 6 hours).3
The study showed that IV ibuprofen provided a
signiﬁcant reduction (430%) in both pain intensity
and narcotic use in surgical patients in the postope-
rative period.
Although the current prescribing information rec-
ommends that the infusion time for IV ibuprofen be371
Table III. Extent of exposure to intravenous
ibuprofen.
No. of Doses
Intravenous Ibuprofen
(N ¼ 300)
Single 252 (84%)
Multiple 48 (16%)
2 doses 17 (6%)
3 doses 4 (1%)
4 doses 27 (9%)
Table IV. Types of surgical procedures during
which ibuprofen infusion was admini-
stered. Data are presented as number
(%) of patients.
Type of Procedure
Intravenous Ibuprofen
(N ¼ 300)
Hernia repair 41 (14)
Hysterectomy 40 (13)
Cholecystectomy 29 (10)
Knee arthroplasty 27 (9)
Hip arthroscopy 23 (8)
Cystectomy 22 (7)
Hip arthroplasty 20 (6)
Oophorectomy 13 (4)
Rhizotomy 10 (3)
Permanent spinal cord
stimulation
10 (3)
Foot arthroplasty 7 (2)
Mastectomy 6 (2)
Biopsy 6 (2)
Prostatectomy 5 (2)
Laparotomy 5 (2)
Tumor resection 4 (1)
Intrathecal drug delivery
pump
4 (1)
Rectocele repair 3 (1)
Ankle arthroscopy 3 (1)
Foot revision 3 (1)
Meniscectomy 3 (1)
Shoulder arthroscopy 2 (1)
Ankle arthrodesis 2 (1)
Thyroid lobectomy 2 (1)
Pelviscopy 2 (1)
Shoulder manipulation 2 (1)
Other 6 (2)
Clinical Therapeuticsno less than 30 minutes, a healthy volunteer trial was
conducted to evaluate the pharmacokinetics and
safety of equivalent single doses of 800-mg IV ibu-
profen (administered over 5–7 minutes) and 800-mg
oral ibuprofen.7 The study showed that IV ibuprofen
had bioavailability equivalent to oral ibuprofen, but
the mean Cmax of IV ibuprofen was approximately
twice that of the oral dose. The median Tmax of the IV
infusion administered over 5 to 6 minutes was 6.5
minutes compared with 1.50 hours for the oral dose.
No safety concerns were noted with the rapid infusion
time in these healthy volunteers. It would be beneﬁcial
to plan a study comparing the pharmacokinetic
proﬁle, clinical effects, and incidence of the adverse
reactions between the 2 modes of IV ibuprofen
administration: 5- to 10-minute versus a 30-minute
infusion. In the present study, 22% of patients (65 of
300) who received rapid IV ibuprofen infusions
experienced adverse events, and the most common
adverse event was infusion site reaction. The incidence
of adverse effects was higher in patients receiving
multiple infusions of ibuprofen. Because the majority
of the adverse events were related to infusion site
reactions, it is reasonable to expect a correlation
between the incidence of such events and the fre-
quency of drug administration. Another possible
explanation is that patients requiring repeated doses
of ibuprofen were sicker and more prone to adverse
reactions.
The infusion site pain safety results from the
present study are consistent with other IV analgesic
infusion pain safety data. Previous IV analgesic studies
have reported a 5% to 29% incidence of infusion site
pain,11–13 and propofol has exhibited up to a 60%
incidence.14 Injection site pain ranging from 19% to37229% was reported with ketorolac, another injectable
NSAID.11
In previous studies of IV ibuprofen in surgical
patients,4,5,9 up to 90% of patients experienced
an adverse event; all patients received concomitant
morphine during these studies; adverse events were
collected regardless of investigator assessment of re-
lationship to IV ibuprofen. Previous studies and data
collected in this trial suggest that a more rapidVolume 37 Number 2
Table V. Vital signs at baseline and 4 hours after the initial infusion of intravenous ibuprofen. Data are
presented as mean (SD).
Vital Sign Before Surgery (N ¼ 300) Postsurgery (Hour 4) (N ¼ 300)
Temperature, 1F 97.9 (0.73) 97.6 (0.82)
Pulse rate, beats/min 74 (12.5) 74 (12.9)
Respiratory rate, breaths/min 18 (2.9) 16 (3.5)
Systolic blood pressure, mm Hg 130 (18.7) 123 (16.8)
Diastolic blood pressure, mm Hg 76 (11.9) 70 (11.0)
T.J. Gan et al.infusion of IV ibuprofen does not pose a safety risk to
patients.
All NSAIDS contain label warnings and precau-
tions regarding the risk of gastrointestinal bleeding or
ulceration, cardiovascular risks, renal and hepatic
injury, and bleeding related to platelet dysfunction.
However, these treatment-related complications are
predominantly associated with long-term drug use,
whereas acute perioperative use of NSAIDs is consid-
ered relatively safe. Previous studies with IV ibuprofen
have not demonstrated any increased risk of serious
adverse events.3–5 Moreover, no cases of perioperative
bleeding, cardiovascular and hepatorenal complica-
tions, or gastrointestinal ulceration were observed.
These data are consistent with a recently published
meta-analysis examining the safety of NSAIDs, which
demonstrated no short-term serious gastrointestinal
outcomes such as bleeding or perforation.15 Long-
term studies showed an association between NSAID
intake and occurrence of serious adverse events.
However, ibuprofen consistently had been at the
lower end of toxicity rankings, whereas ketorolacTable VI. Number (%) of patients experiencing
adverse events.
Adverse
Event
Single Dose
(n ¼ 252)
Multiple
Doses
(n ¼ 48)
Total
(N ¼ 300)
Any adverse
event
49 (19) 16 (33) 65 (22)
Mild 25 (10) 7 (15) 32 (11)
Moderate 16 (6) 9 (19) 25 (8)
Severe 8 (3) 0 8 (3)
February 2015and azapropazone demonstrate a higher risk.16 The
study found that the risk of bleeding was increased
with advancing age, presence of arterial hypertension,
history of bleeding, and use of anticoagulant agents.
The present trial was 1 of 2 Phase IV, open-label
studies conducted to investigate the safety of a shortened
infusion time of IV ibuprofen. A complementary study
(Part 1 of the study) in hospitalized patients with existing
pain and fever found that treatment with IV ibuprofen
resulted in adverse events in 43 (29%) of the 150
patients.8 According to study results, the most common
adverse event experienced by patients was pain at the
infusion site (22 [16%] of 150 patients [mild in 15,
moderate in 5, and severe in 2]) (NCT01334944).
Similar results were observed in the present study, in
which 65 (22%) of the 300 patients experienced adverse
events. The most common adverse event was in-
fusion site reactions (42 of 300 [14%]). No patient died
during the study, and no serious adverse events wereTable VII. Adverse events occurring in Z3% of
patients.
Adverse Event
No. (%) of Patients
(N ¼ 300)
Infusion site reaction 42 (14)
Nausea 10 (3)
Flatulence 9 (3)
Anemia 10 (3)
Bradycardia* 8 (3)
*In the opinion of the investigator, events of
bradycardia were marked not related to intravenous
ibuprofen.
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Table VIII. Serious adverse events (SAEs).
SAE Term
Investigator Assessment of
Relationship to
Intravenous Ibuprofen
Abdominal
compartment
syndrome
Not related
Rectal hemorrhage Not related
Oxygen saturation
decreased
Not related
Peritoneal adhesions Not related
Hypertension Not related
Airway complication
of anesthesia
Not related
Urinary retention Not related
Bile duct stone Not related
Pneumothorax Not related
Clinical Therapeuticsdetermined by the investigator to be related to ibuprofen
therapy. No incidence of bleeding, cardiovascular
events, renal and/or hepatic injury, gastrointestinal
bleeding, or ulceration were reported in either study.
Mean postoperative VAS scores ranged from 26.3
to 33.4 mm. The pain scores were consistent with a
postoperative study that also initiated IV ibuprofenPain Intensity 
(VAS ov
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Figure. Postoperative pain intensity. Mean pain intensi
scores from time 0 to 360 minutes for patients
ibuprofen before the surgical procedure. Postope
100-mm scale.
374therapy before surgery,3 suggesting that postoperative
pain was well managed. The data support the
hypothesis that IV ibuprofen is a useful baseline
agent in multimodal pain control management in the
perioperative setting.
The study had several limitations. As an open-label,
single-arm study, no control group was included. In
addition, the renal function before and after surgery was
not directly compared in this study. Furthermore, the
type of surgical procedure, anesthesia protocol, and
protocol-deﬁned pain regimen was not controlled.
Although there was an absence of consistency between
surgeries, the variability allowed for a broader assess-
ment of the safety and utility of IV ibuprofen used in
diverse surgical settings with multiple analgesic protocols.
CONCLUSIONS
The results of this trial continue to support a body of
evidence establishing that a 5- to 10-minute infusion
of IV ibuprofen can be safely and effectively admin-
istered in a wide variety of surgical patients experi-
encing mild, moderate, or severe pain. Furthermore,
these results support the safe use of IV ibuprofen as a
baseline therapy in a multimodal analgesic regimen.
A shortened infusion can easily be integrated into the
preoperative analgesia regimen in which IV access has
already been established, decreasing the health pro-
vider’s time spent on administration and thus reducing
the burden on the operating room personnel.Post-procedure
er time)
80
inutes)
240 300 360
32.7 30.9
ty as measured by using visual analog scale (VAS)
administered a single 800-mg dose of intravenous
rative analgesia was not controlled. The VAS used a
Volume 37 Number 2
T.J. Gan et al.ACKNOWLEDGMENTS
All the authors of the manuscript designed the study,
collected the data, performed data analysis and inter-
pretation, wrote the manuscript and made the decision
to submit it for publication. The study sponsors did
not participate in any of the aforementioned steps.CONFLICTS OF INTEREST
Dr. Bergese received honoraria 42 years ago from
Cumberland Pharmaceuticals Inc. All authors (except
Dr. Soghomonyan) received a research grant from
Cumberland Pharmaceuticals Inc. to support the
present trial. The authors have indicated that they
have no other conﬂicts of interest regarding the
content of this article.REFERENCES
1. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative
pain experience: results from a national survey suggest
postoperative pain continues to be undermanaged. Anesth
Analg. 2003;97:534–540. (table of contents).
2. Practice guidelines for acute pain management in the
perioperative setting: an updated report by the American
Society of Anesthesiologists Task Force on Acute Pain
Management. Anesthesiology. 2012;116:248–273.
3. Singla N, Rock A, Pavliv L. A multi-center, randomized,
double-blind placebo-controlled trial of intravenous-
ibuprofen (IV-ibuprofen) for treatment of pain in post-
operative orthopedic adult patients. Pain Med. 2010;11:
1284–1293.
4. Kroll PB, Meadows L, Rock A, Pavliv L. A multicenter,
randomized, double-blind, placebo-controlled trial of
intravenous ibuprofen (i.v.-ibuprofen) in the management
of postoperative pain following abdominal hysterectomy.
Pain Pract. 2011;11:23–32.
5. Southworth S, Peters J, Rock A, Pavliv L. A multicenter,
randomized, double-blind, placebo-controlled trial of
intravenous ibuprofen 400 and 800 mg every 6 hours in
the management of postoperative pain. Clin Ther. 2009;
31:1922–1935.February 20156. Smith HS, Voss B. Pharmacokinetics of intravenous
ibuprofen: implications of time of infusion in the treat-
ment of pain and fever. Drugs. 2012;72:327–337.
7. Pavliv L, Voss B, Pharmacokinetics Rock A. safety, and
tolerability of a rapid infusion of i.v. ibuprofen in healthy
adults. Am J Health Syst Pharm. 2011;68:47–51.
8. Bergese SD, Candiotti K, Ayad SS, Soghomonyan S, Gan
TJ. The Intravenous Ibuprofen Surveillance Trial Investiga-
tional Sites. The Shortened Infusion Time of Intravenous
Ibuprofen Part 1: A Multicenter, Open-Label, Surveillance
Trial to Evaluate Safety and Efﬁcacy. Clin Ther. 2015. In
Press.
9. Caldolor (ibuprofen) Injection, Full Prescribing Informa-
tion. 2009. Cumberland Pharmaceuticals Inc. Accessed
July 30, 2014.
10. Vane JR, Botting RM. Mechanism of action of nonster-
oidal anti-inﬂammatory drugs. Am J Med. 1998;104:2S–
8S, discussion 21S–2S.
11. Zhou TJ, Tang J, White PF. Propacetamol versus ketorolac
for treatment of acute postoperative pain after total hip
or knee replacement. Anesth Analg. 2001;92:1569–1575.
12. Wininger SJ, Miller H, Minkowitz HS, et al. A randomized,
double-blind, placebo-controlled, multicenter, repeat-
dose study of two intravenous acetaminophen dosing
regimens for the treatment of pain after abdominal
laparoscopic surgery. Clin Ther. 2010;32:2348–2369.
13. Moller PL, Juhl GI, Payen-Champenois C, Skoglund LA.
Intravenous acetaminophen (paracetamol): comparable
analgesic efﬁcacy, but better local safety than its prodrug,
propacetamol, for postoperative pain after third
molar surgery. Anesth Analg. 2005;101:90–96. (table of
contents).
14. Jalota L, Kalira V, George E, et al. Prevention of pain on
injection of propofol: systematic review and meta-
analysis. BMJ. 2011;342:d1110.
15. Peterson K, McDonagh M, Thakurta S, et al. Drug class
review: nonsteroidal antiinﬂammatory drugs (NSAIDs):
ﬁnal update 4 report. Portland (OR): Oregon Health &
Science University; 2010. http://www.ncbi.nlm.nih.gov/
books/NBK53955/PubMed. PMID: 21542548.
16. Bjarnason I. Gastrointestinal safety of NSAIDs and over-
the-counter analgesics. Int J Clin Pract Suppl. 2013;178:
37–42.Address correspondence to: Sergio D. Bergese, MD, The Ohio State
University, Departments of Anesthesiology and Neurological Surgery,
410 West 10th Avenue, DNN-429, Columbus, OH 43210. E-mail:
sergio.bergese@osumc.edu375
